Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Clin Genitourin Cancer. 2012 Jun;10(2):77-83. doi: 10.1016/j.clgc.2012.01.010. Epub 2012 Feb 28.
Therapeutic inhibition of pathways involved in angiogenesis has become the standard of care in renal cell carcinoma (RCC). Most currently available antiangiogenic agents inhibit the vascular endothelial growth factor (VEGF) pathway. Although these drugs have produced exciting benefits, some tumors do not respond to these agents. In addition most if not all tumors that initially respond will eventually develop resistance. Tumor escape from antiangiogenic therapy may include various signaling pathways that are involved in angiogenesis, including the fibroblast growth factor (FGF) signaling pathway. Emerging preclinical data suggest that FGF and VEGF act distinctly and synergistically to promote tumor vascularization. The current review discusses the role of FGF signaling in resistance to anti-VEGF therapies and outlines potential therapeutic implications.
在肾细胞癌（RCC）中，抑制血管生成途径的治疗方法已成为标准治疗方法。大多数现有的抗血管生成药物抑制血管内皮生长因子（VEGF）途径。尽管这些药物带来了令人兴奋的益处，但有些肿瘤对这些药物没有反应。此外，大多数（如果不是全部）最初有反应的肿瘤最终都会产生耐药性。肿瘤逃避抗血管生成治疗可能包括涉及血管生成的各种信号通路，包括成纤维细胞生长因子（FGF）信号通路。新出现的临床前数据表明，FGF 和 VEGF 以不同的方式协同作用以促进肿瘤血管生成。本综述讨论了 FGF 信号在抗 VEGF 治疗中的耐药作用，并概述了潜在的治疗意义。
